You are here

Inherited Pancreatic Cancer-Risk Mutation Identified

Finding Could Spur New Targeted Treatments

Scientists have identified a rare inherited gene mutation that dramatically raises the lifetime risk of pancreatic and other cancers.

The discovery, reported in Nature Genetics by investigators from Dana-Farber/Brigham and Women’s Cancer Center, could lead to routine testing of individuals with a strong family history of pancreatic cancer to determine whether they carry the mutation, which occurrs in the gene known as RABL3. “There is evidence that catching pancreatic cancer through screening of high-risk individuals may improve outcomes,” said Sahar Nissim, MD, PhD, first author of the study.

About 10% of pancreatic cancers have a familial pattern, and in most cases the causative genetic flaw isn’t known. One inherited mutation that can predispose individuals to pancreatic cancer occurs in BRCA2, the gene that is also known to cause some breast and ovarian cancers.

The RABL3 mutation was pinpointed when scientists studied a family in which five relatives had pancreatic cancer and multiple family members had other cancers—a pattern suggesting an inherited mutation. The mutation accelerates the movement of a known pancreatic cancer protein, KRAS, within the cell. This alteration facilitates the placement of KRAS in the cell membrane and triggers a series of events that promote cancerous growth. Because KRAS activity is altered in a majority of pancreatic cancers, continued study of the RABL3 mutation’s impact on KRAS activity could provide important insights about pancreatic cancer development as well as a new strategy for targeted therapy, said the scientists.

The researchers emphasized that the RABL3 mutation is rare in the general population but said that testing for it may reveal the genetic predisposition in other families who have an unsolved hereditary cancer syndrome.

Source: Dana-Farber Cancer Institute, August 12, 2019

Recent Headlines

Despite older, sicker patients, mortality rate fell by a third in 10 years
Study finds fewer than half of trials followed the law
WHO to meet tomorrow to decide on international public heath emergency declaration
Study of posted prices finds wild variations and missing data
Potential contamination could lead to supply chain disruptions
Mortality nearly doubled when patients stopped using their drugs
Acasti reports disappointing results for a second Omega-3-based drug
Declining lung cancer mortality helped fuel the progress
Kinase inhibitor targets tumors with a PDGFRA exon 18 mutation